Equities analysts predict that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will report earnings per share of ($0.14) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Infinity Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.12) and the lowest estimate coming in at ($0.18). Infinity Pharmaceuticals also reported earnings of ($0.14) per share during the same quarter last year. The business is expected to report its next quarterly earnings report on Tuesday, November 6th.
On average, analysts expect that Infinity Pharmaceuticals will report full-year earnings of ($0.57) per share for the current fiscal year, with EPS estimates ranging from ($0.67) to ($0.51). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.50) per share, with EPS estimates ranging from ($0.81) to ($0.24). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that cover Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last posted its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.08.
A number of research firms recently commented on INFI. Zacks Investment Research upgraded Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research note on Tuesday, September 25th. ValuEngine cut shares of Infinity Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 2nd.
A number of hedge funds and other institutional investors have recently modified their holdings of INFI. Algert Global LLC bought a new position in Infinity Pharmaceuticals in the second quarter worth about $139,000. Essex Investment Management Co. LLC bought a new position in Infinity Pharmaceuticals in the second quarter worth about $314,000. Wells Fargo & Company MN lifted its holdings in Infinity Pharmaceuticals by 83.1% in the first quarter. Wells Fargo & Company MN now owns 192,493 shares of the biotechnology company’s stock worth $404,000 after acquiring an additional 87,357 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in Infinity Pharmaceuticals by 2,112.9% in the first quarter. GSA Capital Partners LLP now owns 302,154 shares of the biotechnology company’s stock worth $635,000 after acquiring an additional 288,500 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in Infinity Pharmaceuticals by 95.2% in the second quarter. Acadian Asset Management LLC now owns 372,009 shares of the biotechnology company’s stock worth $711,000 after acquiring an additional 181,436 shares during the last quarter. 49.28% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:INFI traded up $0.07 during mid-day trading on Friday, reaching $2.39. The stock had a trading volume of 198,953 shares, compared to its average volume of 577,067. The company has a market capitalization of $154.07 million, a price-to-earnings ratio of -2.88 and a beta of 2.25. Infinity Pharmaceuticals has a 1-year low of $1.65 and a 1-year high of $3.62.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Read More: Investing in Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.